Vanguard Portfolio Management
BBNX

Vanguard Portfolio Management’s Beta Bionics BBNX Stock Holding History

Vanguard Portfolio Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Buy
272,984
+43,942
+19% +$523K ﹤0.01% 2486
2026
Q1 		$2.3M Buy
+229,042
New +$3.39M ﹤0.01% 2559

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Portfolio Management's BBNX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Beta Bionics (BBNX) stake by 19% in Q2 2026, buying an estimated $523K and bringing the position to 272,984 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2486.

Vanguard Portfolio Management first reported a position in BBNX in Q1 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Vanguard Portfolio Management held 272,984 shares of Beta Bionics worth $4.28M as of Q2 2026.
  • Vanguard Portfolio Management bought 43,942 Beta Bionics shares in Q2 2026, an estimated $523K.
  • Beta Bionics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2486 holding.
  • Vanguard Portfolio Management first reported a position in Beta Bionics in Q1 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.